Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC

Date

12 Dec 2024

Session

Poster Display session

Presenters

Yunhuan Liu

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-20. 10.1016/iotech/iotech100741

Authors

Y. Liu1, C. Hu2, L. Cheng2, C. Zhao2, X. Li2, M. Jiang2, C. Zhou3

Author affiliations

  • 1 Tongji University School of Medicine, Shanghai/CN
  • 2 Shanghai Pulmonary Hospital, Shanghai/CN
  • 3 Shanghai East/Oriental Hospital Affiliated to Tongji University - Headquarters/Northern Division, Shanghai/CN

Resources

This content is available to ESMO members and event participants.

Abstract 207P

Background

Immune checkpoint inhibitors (ICIs) pushed therapeutic strategy of NSCLC into a new era. Nevertheless, the clinical benefit of ICI therapy in EGFR-driven NSCLC patients, especially patients resistant to EGFR-TKI was unsatisfactory. Immunosuppressive tumor microenvironment (TME) after EGFR-TKI treatment proved huge influence on the efficacy of ICIs. Investigation of the mechanism underlying suppressive TME and exploration of its potential intervention was the urgent requirement for EGFR-TKI resistant NSCLC research.

Methods

ZEB2 expression in NSCLC cell lines and patients’ samples were assessed utilizing qRT-PCR, western blotting, and IHC. The effect of EGFR-TKI resistance and ZEB2 on TAMs polarization were investigated via qRT-PCR of M1/M2 biomarkers and flow cytometry. The modulation of ZEB2 on cytokines’ secretion was evaluated through qRT-PCR, ELISA and MSD. The direct influence of ZEB2 on promoter regions of cytokines was explored by dual luciferase reporter assay. The regulation of signaling pathway on ZEB2 was analyzed by correlative analysis, the results were consolidated using western blotting. Mouse models were used to further confirm the influence of EGFR-TKI resistance and ZEB2 on TAMs polarization.

Results

EGFR-TKI resistance induced M2 polarization and inhibited M1 polarization of TAMs, which was critical for the formation of immunosuppressive TME. ZEB2 was upregulated in EGFR-TKI resistant NSCLC in vitro, in vivo and in silicon. ZEB2 upregulation could induce M2 polarization and impede M1 polarization of TAMs, demonstrating its essential role in the influence of EGFR-TKI resistant NSCLC on TAMs polarization. Besides, ZEB2 overexpression was dependent on PI3K-Akt pathway which was upregulated after EGFR-TKI resistance in NSCLC. Finally, ZEB2's regulation on TAMs polarization was associated with cytokines’ secretion. Apart from its inducement on TGF-β1 secretion, ZEB2 directly bound to the promoter region of CSF-1 to elevate its secretion.

Conclusions

ZEB2, which was upregulated in EGFR-TKI resistant NSCLC on a PI3K-Akt dependent manner, could induce M2 polarization and hinder M1 polarization via elevating the secretion of CSF-1 and TGF-β1.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.